AbClon FY 2025 Annual ReportBeta
AbClon annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 13, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
AbClon FY 2025 Annual Report Analysis
Business Overview
- • Core business: antibody biopharmaceuticals, including biosynergy and biounique antibodies
- • AffiMab bispecific antibody platform co-developed with Affibody, combining Affibody proteins with antibodies for enhanced stability and efficacy
Management Discussion & Analysis
- • Revenue KRW 4.714B, +101.5% YoY; operating loss KRW 17.636B (-KRW 2.047B YoY); net loss KRW 17.907B (-KRW 1.605B YoY)
- • Operating loss increase driven by R&D costs for antibody and CAR-T pipeline development including AC101 Phase 3 and AT101 Phase 2 clinical trials
Risk Factors
- • Foreign currency net asset exposure USD KRW 272.4M, EUR KRW 120.4M as of FY2025 quarter-end
- • 10% KRW appreciation/depreciation impacts pre-tax profit/loss by ±KRW 39.3M at FY2025 quarter-end
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding